Subscribe
money_istock-504240346_jansucko
jansucko / iStockphoto.com
28 September 2018

CRISPR specialist raises $80m in funding

US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan to pay Editas $90m for development of CRISPR eye treatment
20 March 2017   Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Europe
Are the Broad Institute’s CRISPR patents too broad?
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Biotechnology
CRISPR tech market to reach $1.72m by 2023: report
23 November 2018   The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Allergan to pay Editas $90m for development of CRISPR eye treatment
20 March 2017   Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Biotechnology
CRISPR tech market to reach $1.72m by 2023: report
23 November 2018   The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Europe
Are the Broad Institute’s CRISPR patents too broad?
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.

More on this story

Americas
Allergan to pay Editas $90m for development of CRISPR eye treatment
20 March 2017   Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Biotechnology
CRISPR tech market to reach $1.72m by 2023: report
23 November 2018   The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Europe
Are the Broad Institute’s CRISPR patents too broad?
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers